Prothena Corporation plc (PRTA) Financial Analysis & Valuation | Quarter Chart
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the tre... more
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of nov... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $437.67M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | IE | CEO | Gene G. Kinney |
| IPO Date | 2012-12-20 | CAGR | 14.67% |
| Employees | 67 | Website | www.prothena.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 2.34% | Total Yield | 2.34% |
PRTA chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $208.36M | P/E | -10.07 | Forward P/E | -5.5 | PEG | — |
| P/S | 23.17 | P/B | 4.42 | P/CF | -40.31 | P/FCF | -39.69 |
| Sales | $54.53M | Sales 1Y | 427.32% | Sales 3Y | -5.38% | Sales 5Y | -10.24% |
| EPS | $-0.83 | EPS 1Y | -85.11% | EPS 3Y | -69.68% | EPS 5Y | -55.08% |
| Sales QoQ | -98.02% | EPS QoQ | -160% | Sales QoQ Avg | 60728.66% | EPS QoQ Avg | -130.53% |
| Gross Margin | 43.52% | Operating Margin | -115.09% | Profit Margin | -80.67% | ROCE | -21.57% |
| ROA | -15% | ROE | -15% | Altman Z Score | 11.03 | Piotroski Score | 4 |
| Current Ratio | 25.05 | Quick Ratio | 25.05 | Cash Ratio | 24.72 | Op. CF Ratio | 0.33 |
| Debt/Equity | 0.02 | Debt/Assets | 0.02 | Lt Debt/Equity | 0.01 | Lt Debt/Cap. | 0.01 |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0.18 | Receivables Turnover | — |
| Enterprise Value | $208.36M | P/E Ratio | -10.07 |
| Forward P/E | -5.5 | PEG Ratio | — |
| P/S Ratio | 23.17 | P/B Ratio | 4.42 |
| P/CF Ratio | -40.31 | P/FCF Ratio | -39.69 |
| EPS | $-0.83 | EPS Growth 1Y | -85.11% |
| EPS Growth 3Y | -69.68% | EPS Growth 5Y | -55.08% |
| Revenue Growth 1Y | 427.32% | Gross Margin | 43.52% |
| Operating Margin | -115.09% | Profit Margin | -80.67% |
| ROE | -15% | ROA | -15% |
| ROCE | -21.57% | Current Ratio | 25.05 |
| Quick Ratio | 25.05 | Cash Ratio | 24.72 |
| Debt/Equity | 0.02 | Interest Coverage | — |
| Altman Z Score | 11.03 | Piotroski Score | 4 |
Prothena Corporation plc (PRTA) valuation & financials
Prothena Corporation plc (PRTA) has a market capitalization of $437.67M and trades at a price-to-earnings ratio of -10.1. It operates in the Healthcare sector (Biotechnology).
Prothena Corporation plc's revenue grew +427.3% over the last year.
Prothena Corporation plc's next earnings report is scheduled for November 5, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.21. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)